Shopping Cart

Your shopping cart is currently empty

Omaveloxolone

Name: Omaveloxolone
Brand: TargetMol
SKU: T6919
Price: 38 USD
Availability: InStock
Rating: 5 (10 reviews)

(Synonyms: RTA-408) Copy Product Info

🥰Excellent

Hot

Synonyms: RTA-408

Catalog No. T6919 Copy Product Info

Purity: 99.92%

🥰Excellent

Hot

Omaveloxolone (RTA-408) is an oral, potent, and selective activator of the nuclear factor erythropoietin-related factor 2 (Nrf2) pathway, as well as a low-potency PPARγ agonist. Omaveloxolone inhibits osteoclast formation by suppressing the STING-dependent NF-κB signaling pathway. Omaveloxolone is being investigated for use in ALS, multiple sclerosis, non-alcoholic steatohepatitis, neurodegenerative diseases, and oncology research.

Cas No. 1474034-05-3

Customer service consultation

Pack Size	Price	USA Stock	Global Stock
1 mg	$38	-	In Stock
2 mg	$54	-	In Stock
5 mg	$89	-	In Stock
10 mg	$122	-	In Stock
25 mg	$222	-	In Stock
50 mg	$372	-	In Stock
100 mg	$538	-	In Stock
500 mg	$1,150	-	In Stock
1 mL x 10 mM (in DMSO)	$109	-	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:99.92%

Color:White

Resource Download

COA HNMR LCMS

Product Introduction

Bioactivity

Description	Omaveloxolone (RTA-408) is an oral, potent, and selective activator of the nuclear factor erythropoietin-related factor 2 (Nrf2) pathway, as well as a low-potency PPARγ agonist. Omaveloxolone inhibits osteoclast formation by suppressing the STING-dependent NF-κB signaling pathway. Omaveloxolone is being investigated for use in ALS, multiple sclerosis, non-alcoholic steatohepatitis, neurodegenerative diseases, and oncology research.
Targets & IC50	Human tumor cells:260 nM (GI50), HT29 cells:1.41 μM (EC50), L929 cells:5.25 μM (EC50), NO:4.4 ± 1.8 nM
In vitro	Methods: HT22 cells were treated with Omaveloxolone (100, 500, 1000 nM) for 24 hours, followed by Western blot analysis for NRF2, HO-1, and NQO1. Results: Omaveloxolone dose-dependently upregulated NRF2, HO-1, and NQO1 protein levels. [1] Methods: Human FA patient skin fibroblasts were treated with Omaveloxolone (50 nM) or DMF (10 μM) for 48 hours, followed by DCFDA fluorescence probe detection of reactive oxygen species (ROS) levels. Results: Omaveloxolone significantly reduced basal ROS levels in FA cells. [2]
In vivo	Methods: 10-month-old APP/PS1 transgenic mice (AD model) and wild-type (WT) controls received intraperitoneal injections of Omaveloxolone (1 mg/kg/day, once daily) for 2 consecutive months. Results: Omaveloxolone significantly improved the Y-maze alternation rate, number of platform crossings in the water maze, and time spent in the target quadrant in APP/PS1 mice, demonstrating cognitive enhancement.[1] Methods: Cardio/skeletal muscle-specific FXN knockout mice (FXN-cKO) received oral Omaveloxolone (24 mg/kg/day) mixed with peanut butter from 3 weeks of age until 8 weeks of age (5 weeks total). Results: Omarsolon significantly improved cardiac function: EF increased from 26% to 47.5% (P<0.001), and FS increased from 22% to 42.5%. [2]
Synonyms	RTA-408
Cell Research	For growth inhibition assays, cells are plated in duplicate 96-well culture dishes at 3 x 103 cells per well. The following day, one plate is treated with RTA 408 and the other is immediately processed for the sulforhodamine B (SRB) assay (time 0). Cells in the RTA 408-treated plate are processed for the SRB assay 72 hours after the start of treatment. Percentage of growth relative to vehicle-treated cells is calculated using: [(Ti-Tz)/(C-Tz)] x 100 where (Tz) is the absorbance value at time zero, (C) is absorbance value from vehicle treated wells after 72 hours, and (Ti) is the absorbance value from wells treated with the drug. Dose-response curves are plotted in GraphPad Prism and GI50 values are calculated(Only for Reference)

Chemical Properties

Molecular Weight	554.71
Formula	C₃₃H₄₄F₂N₂O₃
Cas No.	1474034-05-3
Smiles	[H][C@@]12CC(C)(C)CC[C@@]1(CC[C@]1(C)[C@]2([H])C(=O)C=C2[C@@]1(C)CC[C@@]1([H])C(C)(C)C(=O)C(=C[C@]21C)C#N)NC(=O)C(C)(F)F
Relative Density.	1.19 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

Ethanol: 16 mg/mL (28.84 mM), Sonication is recommended.

DMSO: 240 mg/mL (432.66 mM), Sonication is recommended.

H2O: < 1 mg/mL (insoluble or slightly soluble)

In Vivo Formulation

10% DMSO+90% Corn Oil: 3.3 mg/mL (5.95 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

Ethanol/DMSO

	1mg	5mg	10mg	50mg
1 mM	1.8027 mL	9.0137 mL	18.0274 mL	90.1372 mL
5 mM	0.3605 mL	1.8027 mL	3.6055 mL	18.0274 mL
10 mM	0.1803 mL	0.9014 mL	1.8027 mL	9.0137 mL
20 mM	0.0901 mL	0.4507 mL	0.9014 mL	4.5069 mL

DMSO

	1mg	5mg	10mg	50mg
50 mM	0.0361 mL	0.1803 mL	0.3605 mL	1.8027 mL
100 mM	0.0180 mL	0.0901 mL	0.1803 mL	0.9014 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Keywords

TMEM173STINGStimulator of Interferon GenesRTA408RTA 408OmaveloxoloneNrf2MPYSMITAKeap1-Nrf2InhibitorinhibitERISApoptosis

Related Tags: Omaveloxolone chemical structure | Omaveloxolone in vivo | Omaveloxolone in vitro | Omaveloxolone formula | Omaveloxolone molecular weight